HPV16 Positive clinical trials at UC Cancer

• A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC

  open to eligible people ages 18 years and up

  This will be a blinded, placebo-controlled, randomized, phase 2 study in which subjects will be randomly assigned 1:1 to cemiplimab plus placebo or cemiplimab plus ISA101b.

  at UCSD UCSF

Last updated: May 15, 2020